CASSANDRA-PACT-21 Trial Update: Preoperative PAXG vs mFOLFIRINOX in Resectable and Borderline Resectable PDAC

oncodaily - The landscape of early-stage pancreatic ductal adenocarcinoma (PDAC) continues to evolve as clinicians move from surgery-first strategies toward perioperative treatment. Neoadjuvant and perioperative approaches have shown growing promise, yet no […]

AI Summary: New findings from the CASSANDRA study indicate that a neoadjuvant quadruplet PAXG regimen significantly improves event‐free survival versus traditional mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, suggesting a potential shift in treatment guidelines.

#healthcare #pharmaceuticals #publichealth #drugdevelopment

Advancing and Learning More About New Treatments for Pancreatic Cancer Every Day – Dana-Farber Cancer Institute

6 months / oncodaily

Yan Leyfman: New Advances in Pancreatic Cancer Immunotherapy

6 months / oncodaily

Allogeneic Stem Cell–Engineered Mesothelin-Redirected CAR-NKT Cells for Orthotopic and Metastatic Pancreatic Cancer

6 months / oncodaily

CASSANDRA-PACT-21 Trial Update: Preoperative PAXG vs mFOLFIRINOX in Resectable and Borderline Resectable PDAC

6 months / oncodaily

Neoadjuvant Quadruplet PAXG Regimen Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable PDAC

6 months / esmo

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Infectious Disease, Mergers and Acquisitions, Rural Health, Pharmaceuticals and look for the RSS link.

StackHealth Time Machine

More StackHealth